PolyXen 平台 :PolyXen是蛋白质和肽药物输送的使能平台技术。它使用生物聚合物聚唾液酸(PSA)来延长药物的半衰期,并可能提高治疗肽和蛋白质的稳定性。附着部位和PSA链的长度都可以通过改变分子的表观流体力学半径来影...查看全文
牛股小红书2022-04-28 13:48
$Xenetic Biosciences(XBIO)$ 与CLS Therapeutics签署了独家许可和再许可协议,以开发其基于DNA酶的介入性肿瘤学平台,旨在改善现有治疗,包括免疫疗法。
根据协议,Xenetic拥有CLS知识产权的独家许可证,用于在癌症中使用DNA酶,包括DNA酶与标准疗法(包括化疗、放疗和检查点抑制剂)的系统联...查看全文
$Xenetic Biosciences(XBIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001683168-19-003913 Size: 5 KB 网页链接
$Xenetic Biosciences(XBIO)$ 8-K Current report, item 5.07 Accession Number: 0001683168-19-003909 Act: 34 Size: 31 KB 网页链接
$Xenetic Biosciences(XBIO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001683168-19-003668 Act: 34 Size: 288 KB 网页链接
$Xenetic Biosciences(XBIO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001683168-19-003653 Act: 34 Size: 2 MB 网页链接
$Xenetic Biosciences(XBIO)$ DEF 14A - Other definitive proxy statements Filed: 2019-11-08 AccNo: 0001683168-19-003504 Size: 639 KB 网页链接
$Xenetic Biosciences(XBIO)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-10-23 AccNo: 0000944809-19-000072 Size: 67 KB 网页链接
$Xenetic Biosciences(XBIO)$ 8-K - Current report Filed: 2019-10-08 AccNo: 0001683168-19-003199 Size: 54 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Xenetic Biosciences(XBIO)$ 8-K - Current report Filed: 2019-09-30 AccNo: 0001683168-19-003103 Size: 21 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$Xenetic Biosciences(XBIO)$ EFFECT - Notice of Effectiveness Filed: 2019-09-23 AccNo: 9999999995-19-002156 Size: 1 KB 网页链接
$Xenetic Biosciences(XBIO)$ S-3 - Registration statement under Securities Act of 1933 Filed: 2019-09-13 AccNo: 0001683168-19-002928 Size: 180 KB 网页链接